The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.

Company Guidance -

Q1 2025

During the Fate Therapeutics Q1 2024 earnings call, the company provided guidance on its clinical and financial outlook. Key program initiatives were discussed, including the FT819 CAR T-cell and FT522 CAR NK cell programs, with notable translational data presented at the American Society of Gene and Cell Therapy Annual Meeting. The company highlighted its plans to achieve several clinical milestones across its iPSC product pipeline, targeting both cancer and autoimmune diseases. Financially, Fate Therapeutics raised $100 million through an underwritten offering and private placement, ending the first quarter with approximately $391 million in cash. Operating expenses for the full year are projected between $215 million and $230 million, with a year-end cash balance exceeding $270 million. The company's strategic focus is on demonstrating the disease-modifying potential of its therapies while maintaining a strong financial position to support ongoing and future clinical development.

FT819 and FT522 Data Presentation

Presented promising data from FT819 and FT522 programs at the ASGCT Annual Meeting, showing potential disease-modifying effects and immune reset in B-cell-mediated autoimmune diseases.

First Lupus Patient Treated

The first lupus patient was treated with FT819, showing no notable adverse events post-treatment.

Strong Financial Position and Fundraising

Raised $100 million through an underwritten offering and a private placement, ending the quarter with $391 million in cash, cash equivalents, and investments.

FT522 Safety Assessment

First 3 patients in FT522 study completed safety assessment without dose-limiting toxicities.

Fate Therapeutics (FATE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FATE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2025	2025 (Q2)	-0.34 / -	-0.33	―	―	―
May 13, 2025	2025 (Q1)	-0.38 / -0.32	-0.47	31.91% (+0.15)	―	―
Mar 05, 2025	2024 (Q4)	-0.43 / -0.44	-0.45	2.22% (+0.01)	―	―
Nov 12, 2024	2024 (Q3)	-0.42 / -0.40	-0.46	13.04% (+0.06)	―	―
Aug 13, 2024	2024 (Q2)	-0.46 / -0.33	-0.54	38.89% (+0.21)	―	―
May 09, 2024	2024 (Q1)	-0.47 / -0.47	-0.19	-147.37% (-0.28)	―
Feb 26, 2024	2023 (Q4)	-0.52 / -0.45	-0.58	22.41% (+0.13)	―
Nov 08, 2023	2023 (Q3)	-0.56 / -0.46	-0.86	46.51% (+0.40)	―
Aug 08, 2023	2023 (Q2)	-0.59 / -0.54	-0.79	31.65% (+0.25)	―
May 03, 2023	2023 (Q1)	-0.62 / -0.19	-0.68	72.06% (+0.49)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FATE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$1.00	$0.96	-4.00%
Mar 05, 2025	$0.90	$1.04	+15.56%
Nov 12, 2024	$2.38	$2.17	-8.82%
Aug 13, 2024	$3.34	$3.27	-2.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fate Therapeutics Inc (FATE) report earnings?

Fate Therapeutics Inc (FATE) is schdueled to report earning on Jul 30, 2025, TBA (Confirmed).

What is Fate Therapeutics Inc (FATE) earnings time?

Fate Therapeutics Inc (FATE) earnings time is at Jul 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FATE EPS forecast?

FATE EPS forecast for the fiscal quarter 2025 (Q2) is -0.34.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing